Publications by authors named "Steven Ripa"

Claim this Profile
S
Safety and effectiveness of once-daily Hysingla extended-release tablets in patients with baseline depression or anxiety.
Louise Taber, Ellie He, Steven R Ripa

Pain Manag· November 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluation of the Ototoxicity Potential of Once-Daily, Single-Entity Hydrocodone in Patients with Chronic Pain: Results of Two Phase-3 Clinical Studies.
Kathleen Campbell, J Walter Kutz, Angela Shoup, Warren Wen, Shau Yu Lynch, Steven R Ripa

Pain Physician· July 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Use of immediate-release opioids as supplemental analgesia during management of moderate-to-severe chronic pain with buprenorphine transdermal system.
Sanford Silverman, Robert B Raffa, Marc J Cataldo, Monica Kwarcinski, Steven R Ripa

J Pain Res· May 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effects of buprenorphine on QT intervals in healthy subjects: results of 2 randomized positive- and placebo-controlled trials.
Stephen C Harris, Joel Morganroth, Steven R Ripa, Michael D Thorn, Salvatore Colucci

Postgrad Med· January 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety of buprenorphine transdermal system in the management of pain in older adults.
Joseph V Pergolizzi, Robert B Raffa, Zachary Marcum, Salvatore Colucci, Steven R Ripa

Postgrad Med· January 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Hysingla® ER, a once-daily, single-entity hydrocodone with abuse-deterrent properties in treating chronic nonmalignant and nonneuropathic pain in patients with osteoarthritis.
Louise Taber, Stacy Baldridge, Ellie He, Steven R Ripa

Postgrad Med· January 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Subgroup Analysis Found no Diminished Response to Buprenorphine Transdermal System Treatment for Chronic Low Back Pain Patients Classified with Depression.
Aaron Yarlas, Kate Miller, Warren Wen, Shau Yu Lynch, Catherine Munera, Steven R Ripa

Pain Pract· April 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Buprenorphine Transdermal System Improves Sleep Quality and Reduces Sleep Disturbance in Patients with Moderate-to-Severe Chronic Low Back Pain: Results from Two Randomized Controlled Trials.
Aaron Yarlas, Kate Miller, Warren Wen, Shau Yu Lynch, Steven R Ripa

Pain Pract· March 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-term safety and effectiveness of once-daily, single-entity, extended-release hydrocodone over 76 weeks of an open-label study in patients with chronic noncancer and nonneuropathic pain.
Louise Taber, Shau Yu Lynch, Ellie He, Steven R Ripa

Postgrad Med· January 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A multicenter, randomized, double-blind, placebo-controlled trial to assess the efficacy and safety of single-entity, once-daily hydrocodone tablets in patients with uncontrolled moderate to severe chronic low back pain.
Warren Wen, Steve Sitar, Shau Yu Lynch, Ellie He, Steven R Ripa

Expert Opin Pharmacother· November 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
1
12-Month safety and effectiveness of once-daily hydrocodone tablets formulated with abuse-deterrent properties in patients with moderate to severe chronic pain.
Warren Wen, Louise Taber, Shau Yu Lynch, Ellie He, Steven Ripa

J Opioid Manag· November 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Buprenorphine transdermal system compared with placebo reduces interference in functioning for chronic low back pain.
Aaron Yarlas, Kate Miller, Warren Wen, Shau Yu Lynch, Catherine Munera, Steven R Ripa

Postgrad Med· January 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The impact of buprenorphine transdermal delivery system on activities of daily living among patients with chronic low back pain: an application of the international classification of functioning, disability and health.
Kate Miller, Aaron Yarlas, Warren Wen, Bradley Dain, Shau Yu Lynch, Steven R Ripa

Clin J Pain· December 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Application site adverse events associated with the buprenorphine transdermal system: a pooled analysis.
Warren Wen, Shau Yu Lynch, Catherine Munera, Ruth Swanton, Steven R Ripa

Expert Opin Drug Saf· May 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Buprenorphine transdermal system and quality of life in opioid-experienced patients with chronic low back pain.
Kate Miller, Aaron Yarlas, Warren Wen, Bradley Dain, Shau Yu Lynch, Steven R Ripa

Expert Opin Pharmacother· February 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A randomized, placebo-controlled study of the impact of the 7-day buprenorphine transdermal system on health-related quality of life in opioid-naïve patients with moderate-to-severe chronic low back pain.
Aaron Yarlas, Kate Miller, Warren Wen, Bradley Dain, Shau Yu Lynch, Steven R Ripa

J Pain· January 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A randomized, 14-day, double-blind study evaluating conversion from hydrocodone/acetaminophen (Vicodin) to buprenorphine transdermal system 10 μg/h or 20 μg/h in patients with osteoarthritis pain.
Steven R Ripa, Bill H McCarberg, Catherine Munera, Warren Wen, Craig J Landau

Expert Opin Pharmacother· June 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of the seven-day buprenorphine transdermal system in opioid-naïve patients with moderate to severe chronic low back pain: an enriched, randomized, double-blind, placebo-controlled study.
Deborah J Steiner, Steve Sitar, Warren Wen, Gosford Sawyerr, Catherine Munera, Steven R Ripa

J Pain Symptom Manage· December 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of buprenorphine transdermal system (BTDS) for chronic moderate to severe low back pain: a randomized, double-blind study.
Deborah Steiner, Catherine Munera, Martin Hale, Steven Ripa, Craig Landau

J Pain· November 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Buprenorphine transdermal delivery system in adults with persistent noncancer-related pain syndromes who require opioid therapy: a multicenter, 5-week run-in and randomized, double-blind maintenance-of-analgesia study.
Craig J Landau, William D Carr, Albert J Razzetti, Nelson E Sessler, Catherine Munera, Steven R Ripa

Clin Ther· October 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis